Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape

Snapshot: 2026-09-04

Hubei Multiple Myeloma Active Trials & Centers

As of 2026-09-04, there are 40 active clinical trials for multiple myeloma hosted across 9 tertiary medical centers in Hubei (including Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Yichang Central People's Hospital, etc.).

Active Trials

Hospitals

Therapies

CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (9)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyYichang Central People's HospitalXiangyang Central HospitalZhongnan Hospital of Wuhan UniversityEnshi Tujia and Miao Autonomous Prefecture Central HospitalHubei Cancer HospitalTongji Medical College of Huazhong University of Science and TechnologyRenmin Hospital of Wuhan University

Active Studies in Hubei (40)

Population synthesized by CMDN

Showing 0 published English records of 40 registry trials.

All 40 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.

Back to National Landscape Filter Local Trials in the Trial Hub